Anti-BRD3 antibody - C-terminal (ab228936)
Key features and details
- Rabbit polyclonal to BRD3 - C-terminal
- Suitable for: WB
- Reacts with: Mouse, Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-BRD3 antibody - C-terminal
See all BRD3 primary antibodies -
Description
Rabbit polyclonal to BRD3 - C-terminal -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat, Rhesus monkey -
Immunogen
Recombinant fragment within Human BRD3 (C terminal). The exact sequence is proprietary.
Database link: Q15059 -
Positive control
- WB: HeLa nuclear extract. Mouse liver whole cell lysate.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.00
Preservative: 0.025% Proclin 300
Constituents: 79% PBS, 20% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab228936 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/20000. Predicted molecular weight: 80 kDa.
|
Notes |
---|
WB
1/1000 - 1/20000. Predicted molecular weight: 80 kDa. |
Target
-
Tissue specificity
Ubiquitous. -
Involvement in disease
Note=A chromosomal aberration involving BRD3 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;9)(q14;q34) with NUT which produces a BRD3-NUT fusion protein. -
Sequence similarities
Contains 2 bromo domains. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 8019 Human
- Entrez Gene: 67382 Mouse
- Entrez Gene: 362092 Rat
- Omim: 601541 Human
- SwissProt: Q15059 Human
- SwissProt: Q8K2F0 Mouse
- Unigene: 522472 Human
- Unigene: 654869 Human
see all -
Alternative names
- BRD 3 antibody
- Brd3 antibody
- BRD3_HUMAN antibody
see all
Images
-
Anti-BRD3 antibody - C-terminal (ab228936) at 1/1000 dilution + HeLa (human epithelial cell line from cervix adenocarcinoma) nuclear lysate at 20 µg
Secondary
HRP-conjugated anti-rabbit IgG
Developed using the ECL technique.
Predicted band size: 80 kDa7.5% SDS-PAGE
-
Anti-BRD3 antibody - C-terminal (ab228936) at 1/20000 dilution + Mouse liver whole cell lysate at 20 µg
Secondary
HRP-conjugated anti-rabbit IgG
Developed using the ECL technique.
Predicted band size: 80 kDa7.5% SDS-PAGE
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab228936 has not yet been referenced specifically in any publications.